Bioxytran (BIXT) Stock Statistics & Valuation Metrics

Bioxytran has a market cap or net worth of $8.53M. The enterprise value is ―.

Bioxytran has 98,898,384 shares outstanding. The number of shares has decreased by -2.65% in one year.

Bioxytran’s return on equity (ROE) is 1.32 and return on invested capital (ROIC) is 318.55%.

The current PE Ratio of Bioxytran is ―. Bioxytran’s PEG ratio is 0.11.

In the last 12 months, Bioxytran had revenue of 0.00 and earned -2.37M in profits. Earnings per share was -0.02.

In the last 12 months, operating cash flow was -247.17K and capital expenditures -10.33K, giving a free cash flow of -257.50K billion.

Bioxytran pays an annual dividend of ―, resulting in a dividend yield of ―

Bioxytran upcoming earnings date is ―, ―.

Bioxytran as a current ratio of <0.01, with Debt / Equity ratio of -29.44%

In the past 12 months, Bioxytran has paid 0.00 in taxes.

Bioxytran EV to EBITDA ratio is -6.09, with an EV/FCF ratio of -161.43.

Bioxytran has $14.50K in cash and marketable securities with $855.00K in debt, giving a net cash position of -$840.50K billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Bioxytran is ―, which is 11.43% higher than the current price. The consensus rating is ―